Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2016 · 10-Q
Revenue$1.44M$1.44M−23.1% vs Q3 2015 Net Income$31.20M$31.20MN/M vs Q3 2015 EPS Diluted$0.30$0.30N/M vs Q3 2015 Gross Profit$1,441,000−23.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$8,915,000N/M Margins · derivedGross margin100.0%±0.0 pt vs Q3 2015
Operating margin-663.1%+249.6 pt vs Q3 2015
Net margin2165.1%+2892.2 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 4, 2016 · 35 d after period end